ING Groep NV Has $9.42 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

ING Groep NV boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 399.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,221 shares of the life sciences company's stock after purchasing an additional 57,774 shares during the quarter. ING Groep NV's holdings in Illumina were worth $9,418,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. acquired a new position in Illumina during the second quarter worth $34,000. Versant Capital Management Inc grew its holdings in shares of Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock worth $34,000 after buying an additional 246 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock valued at $56,000 after acquiring an additional 168 shares during the last quarter. Focused Wealth Management Inc acquired a new position in shares of Illumina during the 3rd quarter valued at about $63,000. Finally, Hollencrest Capital Management purchased a new position in Illumina during the third quarter worth approximately $63,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Down 5.1 %

Shares of NASDAQ ILMN traded down $7.19 during mid-day trading on Friday, reaching $135.05. The company had a trading volume of 4,740,357 shares, compared to its average volume of 2,019,896. The stock has a fifty day moving average of $139.44 and a two-hundred day moving average of $124.23. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a 12-month low of $92.69 and a 12-month high of $156.66. The company has a market capitalization of $21.42 billion, a price-to-earnings ratio of -13.76 and a beta of 1.13.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ILMN shares. UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 target price for the company in a research note on Thursday, October 17th. Stephens boosted their price objective on Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research report on Tuesday. Finally, Piper Sandler cut their price target on Illumina from $195.00 to $185.00 and set an "overweight" rating on the stock in a report on Monday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.